Brinckerhoff Quoted on Amgen v Sandoz Ruling

23 July 2015 Intellectual Property News

Intellectual Property

Partner Courtenay Brinckerhoff was quoted in an Intellectual Property magazine article, “Amgen v Sandoz: BPCIA is a ‘Mystery Inside an Enigma,’” on July 23, 2015. The article discussed the Amgen v Sandoz decision, which ruled that biosimilar applicants can opt out of the U.S. Biologics Price Competition and Innovation Act’s patent resolution procedures and information disclosure/notice-of-commercial-marketing provisions.

Brinckerhoff was quoted saying, “It will be interesting to see if any biosimilar applicants go all in, ante up their biosimilar applications and play along. The court held that 42 USC § 262 (l)(8)(A) is a ‘standalone notice provision’ that requires a biosimilar applicant to give 180-days prior notice of commercial marketing to the reference product sponsor, but must wait to do so until after its biosimilar application is approved.”

Related Services


RCE PTA Carve-Out Resumes After Interference
18 September 2019
The Ninth Circuit Expected to Rule that Doctors Can Be Wrong in the Winter v. Gardens False Claims Act Case
18 September 2019
Legal News: Government Enforcement Defense & Investigations
Upcoming Webinar: Maximizing Solar Tax Credits - Navigating the Start of Construction Rules (Part 1)
17 September 2019
Renewable Energy Outlook
When Birds Finally Find a Nest
17 September 2019
Dashboard Insights
Lacktman, Ferrante Cited in mHealth Intelligence About Ryan Haight Act
19 September 2019
mHealth Intelligence
Tinnen Discusses How Viewpoint Diversity Helps Businesses Thrive
18 September 2019
Vernaglia Comments on AHA v Azar Decision
18 September 2019
MedPage Today
Lach Comments on Launch of New Group
16 September 2019
BizTimes Milwaukee
MedTech Impact Expo & Conference
13-15 December 2019
Las Vegas, NV
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
BRG Healthcare Leadership Conference
06 December 2019
Washington, D.C.
CTeL Telehealth Fall Summit 2019
04-06 December 2019
Washington, D.C.